Bureaucratic issues. Diabetics are the ones who pay. «We learned with dismay that with AIFA's determination of 10 October (published in the Official Journal of 23 October) the transfer of the drug Baqsimi (glucagon in nasal spray version) to class C, i.e. paid for, was ordered. An obligatory step, it seems, as Lilly, the manufacturing company, has sold this drug to another which does not yet have an office in Italy and cannot, therefore, proceed with the renegotiation of the price with Aifa".

The complaint comes from the Sardinian patients' association, Diabete Zero Odv, in a note in which it says it is concerned " as currently only glucagon to be administered through injections can be provided free of charge".

Despite having received reassurances "that Lilly will ensure that this life-saving drug remains available in this transitional period", the association explains that "the spray version has made administration to children much easier, not only by family members but also of school staff. Our association is, in fact, currently committed to encouraging the inclusion of diabetic children and young people in school as much as possible. During this activity, quite a few difficulties and fears emerged regarding, above all, the administration of drugs and the management of hypo- and hyperglycaemia."

«We have already expressed our concerns to the Region which immediately demonstrated sensitivity and is studying a solution», supports Diabete Zero Odv, «We also believe it is appropriate that at a national level procedures are studied which, in these cases, allow an extension of the permanence of the drug in class A for a transitional period. We also appeal to the ethical sense of pharmaceutical companies to ensure that their legitimate choices do not translate into more or less serious inconveniences for patients."

(Unioneonline)

© Riproduzione riservata